Introduction

A
survey was sent to all biotechnology stakeholders in Singapore between 20 March and 10 April 2006. It consists of the following topics: the strengths of Singapore biotechnology, the strengths of alliances and biopartnering in Singapore (BioSingapore as the Singapore industry peak body) and whether Singapore is one of the top five global hubs. In addition, the survey participants were asked to provide comments on which sectors are regarded as "hot" and which areas are invested heavily in Singapore's biotechnology sector. They were also asked to comment on what were their expectations for Singapore's biotechnology sector in 2010. Their confidential views were collected and presented in this article. Furthermore, survey participants were asked to rate (rating of 1 being the lowest and 10 being the highest) on the above topics.
Overall Strengths of Singapore Biotechnology
Some stakeholders believe that, at present, Singapore's biomedical sector appears to be focused on basic biomedical research, pharmaceuticals and drug development. However, they noted this emphasis was shifting to other areas.
The hot areas (invested in heavily at present by private investors) are biomedical, pharmaceuticals, drug discovery, bioimaging, stem cells, cohort studies, neurosciences, bioengineering, biomarkers, biochips, vaccine production, biofermentation, medical devices , health IT solutions, bioinformatics and microarrays. The stakeholders felt that the hot topics normally involved something that the Singaporean government has a stake in, citing a current example of ESI, a company which the Singaporean government invested in (S$45 million /US$28 million).
A large portion of the government funding is allocated to research and development (R & D) activities via A*STAR (Agency for Science, Technology and Research), a Singapore agency actively involved in research. A*STAR also provides funding/scholarships for the training of scientists. A*STAR covers a wide spectrum of biotechnology sectors, including stem cell research (Singapore government is very supportive of stem cell research).
The survey revealed that, although agricultural biotechnology, vaccine production, natural medicine, alternative therapeutics and plant biotechnology have a bright economic future globally, the Singapore government and other key government industries are not so keen in investing money in these areas. The stakeholders believe that other ASEAN countries such as China, India, Japan and Thailand will benefit in these areas, especially in agricultural biotechnology in the long term.
The Singapore venture capital market is growing at present and Singapore's biotechnology sector has already noticed a number of venture capitalists focusing on Singapore biotechnology. There are a number of networking sessions regularly scheduled to bring these venture capitalists to meet emerging biotechnology companies. Using the current platforms, the Singapore government can further provide more insights to the international venture capitalists on the potential of Singapore's biotech industry.
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International Alliances and Biopartnering
Some stakeholders believe that they have noticed positive efforts in biopartnering, with A*STAR and Singapore Biopolis fronting the initiatives in joint ventures (JVs) with emerging biotech companies in the US, Europe and Asia. Many noted that this area has been the major achievement of the Singapore government as it has succeeded, over the years, in attracting top pharma companies (Novartis, GSK, Eli Lily), research institutions (John Hopkins) and top scientists (Sir David Lane, Professor Alan Coleman) to Singapore.
The life sciences sector (pharma and biotech) has leapfrogged in terms of industry (manufacturing) output in the recent years. Some participants praised the government for playing a significant role in facilitating international alliances and biopartnering (Table 1) .
BioSingapore (the Singapore Biotechnology Industry Peak Body) is a good platform for SME (Table 2) and stakeholders believe that BioSingapore should play a more active role in creating alliances and biopartnering with other ASEAN counterparts rather than focus on western counterparts and Australia. Some responses indicated that BioSingapore, universities, institutes, Singapore private companies and multinational companies are increasing their alliances and biopartnering activities. Thus, positive results from these collaborations are expected. Most stakeholders expect these international alliances and biopartnering to be successful in Singapore. In many ways, these areas are already given top priority by the Singapore government.
Multinational companies have their own network and will continue to come to Singapore, even when China and India develop their own biotechnology sectors and networks. Singapore will still be a useful platform to access other ASEAN countries. However, some participants feel that the alliances and biopartnering are still a work in progress as many projects are still in the precommercial phase. Therefore, it is too early to tell whether theses nascent relationships will come to fruition. Some large and seemingly impressive deals have been negotiated but it remains to be seen if they will prove profitable in the long run.
In terms of significant economic returns (on par with investment funds committed), the partnering trends are regarded as being too far downstream with Singapore expecting little advantages in terms of cost. Positive responses also indicated an expectation of at least two private companies having novel drug molecules in Phase 2 trials then. In addition, they expect at least three or four companies to have ongoing clinical trials and five to ten companies with reasonable pipelines. Homegrown innovations/inventions for partnerships, new innovative products for world markets and turnover are expected to triple in 2010 as compared to 2006. More venture capital and private investment; more collaborations with multinational companies, private SME, universities and institutes; and more incubators like Singapore Biopolis, private cluster and an agriculture hub are also expected by 2010.
Some survey responses indicated that with the Singapore government's strong infrastructure and support, Singapore is a conducive environment and a hotbed for biotech companies internationally to engage in cutting edge research. In addition, some survey participants mentioned the recently announced Science and Technology Plan 2010, which has about S$7.5 billion (US$4.7 billion) committed to fund public and private R & D over the next five years, as a noteworthy development.
Another point to note is that Singapore is moving too slowly in respect of global dynamics. There needs to be less government participation (from a profit perpspective) and, contemporaneously, more liberalized governmental support structure for starts ups and SMEs. Singapore government, need to focus on the global stage whilst facilitating more liberal ventures stakes (not controlling or red tape) in SMEs and start ups. The stakeholders also indicated that although there is a good reservoir of available venture capital, risk acceptance is akin to a risk averse "banker's mentality".
